Avian Influenza
Conditions
Keywords
A/H5N8, Adjuvants, AS03, Inactivated, Influenza, MF59, Monovalent
Brief summary
This is a Phase I cohort-randomized, double-blind, controlled trial designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine administered at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants. This study will be conducted at 6 sites and enroll 150 (up to 380) males and non-pregnant females, 19 to 64 years old, inclusive who are in good health and meet all eligibility criteria. The entire study duration is approximately 24 months and each subject participation duration is approximately 13 months. The primary objectives are: 1) To assess the safety and reactogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 2) To assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart.
Detailed description
This is a Phase I cohort-randomized, double-blind, controlled trial designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine manufactured by bioCSL administered at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants manufactured by GlaxoSmithKline Biologicals (GSK) and Novartis Vaccines and Diagnostics (NVD), respectively. This study will be conducted at 6 VTEU sites and enroll 150 (up to 380) males and non-pregnant females, 19 to 64 years old, inclusive who are in good health and meet all eligibility criteria. The entire study duration is approximately 24 months and subject participation duration is approximately 13 months. Subjects will be enrolled in one of two cohorts, and within each cohort subjects will be randomized in a 2:2:1 ratio. Subjects in Cohort 1 will be randomly assigned to 1 of 3 treatment arms to receive two doses of the A/H5N8 vaccine at varying antigen dosages (3.75 or 15 mcg HA) with AS03 (30-76 subjects per treatment arm), or to a comparator arm receiving two doses of the A/H5N8 vaccine (15 mcg HA) without adjuvant (15-38 subjects). Subjects in Cohort 2 will be randomly assigned to 1 of 3 treatment arms to receive two doses of the A/H5N8 vaccine at varying antigen dosages (3.75 or 15 mcg HA) with MF59 (30-76 subjects per treatment arm), or to a comparator arm receiving two doses of the A/H5N8 vaccine (15 mcg HA) without adjuvant (15-38 subjects). All subjects will receive the same dosage of vaccine with or without the same adjuvant at both of their first and second study vaccinations, with the exception that subjects in Cohort 1 who do not receive Vaccination 2 prior to February 28, 2017 will receive a second unadjuvanted vaccination with the same antigen dosage as their randomized assignment. All doses will be administered intramuscularly approximately 21 days apart. Primary objectives are: 1) To assess the safety and reactogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 2) To assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of two doses administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. Secondary objectives are: 1) To assess study unsolicited non-serious AEs following receipt of two doses of a monovalent inactivated influenza A/H5N8 virus vaccine administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 2) To assess medically-attended adverse events (MAAEs), including new-onset chronic medical conditions (NOCMCs), potentially immune-mediated medical conditions (PIMMCs), and all serious adverse events (SAEs) following receipt of two doses of a monovalent inactivated influenza A/H5N8 virus vaccine administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants approximately 21 days apart. 3) To assess the serum HAI and Neut antibody responses to a monovalent inactivated influenza A/H5N8 virus vaccine following receipt of one dose administered intramuscularly at different dosages (3.75 and 15 mcg of HA per dose) given with or without AS03 or MF59 adjuvants.
Interventions
DRUGAS03
AS03 oil-in-water emulsion adjuvant.
DRUGMF59
Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
BIOLOGICALMonovalent Influenza A/H5N8 vaccine
Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
1. Provide written informed consent prior to initiation of any study procedures. 2. Are able to understand and comply with planned study procedures and be available for all study visits. 3. Are males or non-pregnant females, 19 to 64 years old, inclusive. 4. Are in good health. -As determined by medical history and physical examination to evaluate acute or currently ongoing chronic medical diagnoses or conditions, defined as those that have been present for at least 90 days, that would affect the assessment of the safety of subjects or the immunogenicity of study vaccinations. Chronic medical diagnoses or conditions should be stable for the last 60 days. This includes no change in chronic prescription medication, dose, or frequency as a result of deterioration of the chronic medical diagnosis or condition in the 60 days prior to enrollment. Any prescription change that is due to change of health care provider, insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition. Similarly, medication changes subsequent to enrollment and study vaccination are acceptable provided there was no deterioration in the subject's chronic medical condition that necessitated a medication change, and there is no additional risk to the subject or interference with the evaluation of responses to study vaccination. Note: Topical, nasal, and inhaled medications (with the exception of inhaled corticosteroids as outlined in the Subject
Exclusion criteria
(see Section 5.1.2), herbals, vitamins, and supplements are permitted. 5. Oral temperature is less than 100.0°F. 6. Pulse is 50 to 115 bpm, inclusive. 7. Systolic blood pressure is 85 to 150 mmHg, inclusive. 8. Diastolic blood pressure is 55 to 95 mmHg, inclusive. 9. Erythrocyte sedimentation rate (ESR) is less than 30 mm per hour. 10. Alanine aminotransferase (ALT) is less than 44 IU/L for females or is less than 61 IU/L for males. 11. Creatinine is less than 1.11 mg/dL for females or is less than 1.38 mg/dL for males. 12. White blood cells (WBC) are greater than 3.9 x10\^3/µL and less than 10.6 x10\^3/µL. 13. Hemoglobin (Hgb) is greater than 11.4 g/dL for females or is greater than 12.4 g/dL for males. 14. Platelets are greater than 139 x10\^3/µL and less than 416 x10\^3/µL. 15. Total bilirubin is less than 1.3 mg/dL. 16. Women of childbearing potential must use an acceptable contraception method from 30 days before first study vaccination until 60 days after last study vaccination. * Not sterilized via tubal ligation, bilateral oophorectomy, hysterectomy, or successful Essure® placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure, and still menstruating or \< 1 year of the last menses if menopausal. * Includes, but is not limited to, non-male sexual relationships, abstinence from sexual intercourse with a male partner, monogamous relationship with vasectomized partner who has been vasectomized for 180 days or more prior to the subject receiving the first study vaccination, barrier methods such as condoms or diaphragms with spermicide or foam, effective intrauterine devices, NuvaRing®, and licensed hormonal methods such as implants, injectables, or oral contraceptives (the pill). 17. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to study vaccination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Geometric Mean Titers of Neut antibodies against the A/H5N8 antigen contained in the study vaccine | Day 43 |
| Geometric Mean Titers of serum HAI antibodies against the A/H5N8 antigen contained in the study vaccine | Day 43 |
| Occurrence of clinical safety laboratory AEs | Day 1-9 |
| Occurrence of solicited injection site and systemic reactogenicity events | Day 1-9 |
| Occurrence of study vaccine-related SAEs | Day 1-387 |
| Percentage of subjects achieving HAI seroconversion against the A/H5N8 antigen contained in the study vaccine | Day 43 |
| Percentage of subjects achieving Neut seroconversion against the A/H5N8 antigen contained in the study vaccine | Day 43 |
| Percentage of subjects achieving serum HAI antibody titer of 1:40 or greater against the A/H5N8 antigen contained in the study vaccine | Day 43 |
| Percentage of subjects achieving serum Neut antibody titer of 1:40 or greater against the A/H5N8 antigen contained in the study vaccine | Day 43 |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of all serious adverse events (SAEs), regardless of the assessment of relatedness | Day 1-387 |
| Percentage of subjects achieving serum HAI antibody titers of 1:40 or greater against the A/H5N8 antigen contained in the study vaccine | Day 1, 8, 22, 29, 43, 202, and 387 |
| Geometric Mean Titers of serum HAI antibodies against the A/H5N8 antigen contained in the study vaccine | Day 1, 8, 22, 29, 43, 202, and 387 |
| Geometric Mean Titers of Neut antibodies against the A/H5N8 antigen contained in the study vaccine | Day 1, 8, 22, 29, 43, 202, and 387 |
| Occurrence of all unsolicited adverse events, regardless of the assessment of seriousness or relatedness | Day 1-22 |
| Occurrence of MAAEs, including NOCMCs, and PIMMCs | Day 1-387 |
| Occurrence of study vaccine-related unsolicited non-serious AEs | Day 1-22 |
| Percentage of subjects achieving HAI seroconversion against the A/H5N8 antigen contained in the study vaccine | Day 8, 22, 29, 43, 202, and 387 |
| Percentage of subjects achieving Neut antibody titers of 1:40 or greater against the A/H5N8 antigen contained in the study vaccine | Day 1, 8, 22, 29, 43, 202, and 387 |
| Percentage of subjects achieving Neut seroconversion against the A/H5N8 antigen contained in the study vaccine | Day 8, 22, 29, 43, 202, and 387 |
Countries
United States
Outcome results
None listed